Given the specific supporting role of eHsp90α in cancer, and the failure of many clinical trials using pan- inhibitors targeting all intracellular Hsp90 chaperone members, several groups have reported on the benefit of selectively inhibiting eHsp90α for reducing tumour metastasis and improving patient survival. This evidence concerns the gene HSP90AA1 and cancer.